Loading...
NPI 1316331481 · Park Ridge, IL · Family Medicine Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rahul Khapekar is a family medicine physician provider located in Park Ridge, Illinois. This profile covers 18 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Rahul Khapekar |
| Address | 1775 Ballard Rd |
| City | Park Ridge |
| State | IL |
| ZIP | 60068 |
| Taxonomy | Family Medicine Physician |
| NPI Enumerated | March 26, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.2M |
| Medicaid | $410 |
Service-line profile: The provider’s Medicare billing is heavily weighted toward intra‑articular hyaluronan injections and image‑guided joint procedures, with large volumes reported for J7320 (326K claims, $1.6M revenue), 77002 (14.1K claims, $1.3M revenue), and 20610 (14.1K claims, $973.5K revenue). This mix — multiple hyaluronan codes (J7320, J7321, J7324, J7328) alongside fluoroscopic guidance and joint injection codes — is consistent with a high‑volume musculoskeletal or injection‑focused ambulatory practice that bills both the medication/device codes and associated image guidance. It also bills office E/M codes (99213, 99212) but those account for a materially smaller share of Medicare revenue.
Medicare revenue concentration: The top three Medicare codes (J7320, 77002, 20610) account for 76.6% of the provider’s total Medicare revenue, indicating a high concentration of billings in a small set of procedural services. Given that J7320 alone represents $1.6M of the $5.2M total, these procedures are the primary drivers of Medicare dollars for this NPI.
Medicaid revenue concentration and scale: Medicaid revenue is essentially immaterial at $410 lifetime, with the top three Medicaid codes accounting for 100.0% of that amount and J7320 representing $300 of Medicaid revenue. In practical terms the provider is effectively single‑payer from a revenue standpoint (Medicare), with negligible Medicaid financial exposure.
Payer mix and scale: Medicare dominates the provider’s publicly reported payor mix — $5.2M in Medicare revenue versus $410 in Medicaid — so utilization and contracting decisions should be evaluated primarily in the Medicare context. Any analysis or network strategy that focuses on Medicaid would deal with a very small volume and limited financial impact for this provider.
National competitive standing on key procedures: For several high‑revenue Medicare codes this provider ranks at the top nationally and is labeled an “extreme outlier,” including J7320 (rank #1 of 462, 100th percentile), 77002 (rank #1 of 7010, 100th percentile), and 20610 (rank #1 of 39752, 100th percentile). These rank positions indicate the provider is a dominant national performer on those specific procedural codes and far above typical national volumes for peers.
In‑state Medicaid positioning and zero‑paid supply codes: On Medicaid the provider’s J7320 activity is modest compared with Medicare (60 claims, $300 revenue; rank #2 of 2 in‑state) and other Medicaid codes show claims with $0 paid (for example Q9967: 497 claims, $0 revenue). The presence of sizable claim counts with $0 average paid/claim in both Medicare (Q9967: 23.6K claims, $0 revenue) and Medicaid suggests frequent reporting of contrast material line items that do not generate direct revenue in the dataset.
Statistical outlier pattern and utilization signal: Numerous Medicare codes billed by this provider are explicitly flagged as “extreme outlier” or “notably above typical national volume” (examples include J7320, 77002, 20610, J7321, 73580, J1020), which signals a concentrated, high‑throughput procedural practice compared with national peers. That pattern is relevant for utilization management and contracting teams evaluating whether these services represent a strategic, high‑volume specialty within the provider’s practice rather than typical primary care mix.
Tenure and operational implication: The NPI was enumerated on 2015-03-26 (~11 years ago), and the combination of a decade‑plus tenure with the reported high procedure volumes implies an established operation focused on musculoskeletal injection and image‑guided services rather than a recent or sporadic enterprising activity. Analysts should interpret current volumes in the context of an experienced practice with a sustained procedural focus.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
18 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | 326,000 | $10 | $1.6M |
| 77002 | The provider uses fluoroscopic guidance to place a needle for biopsy, aspiration, injection, or localization of a device to detect any lesions in any area of the body, except for the spine, or to… | 14,080 | $100 | $1.3M |
| 20610 | In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa and then uses the syringe attachment to the needle to remove fluid or he may inject a… | 14,110 | $70 | $973.5K |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 5,030 | $60 | $291.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,650 | $70 | $182.6K |
| 27369 | The provider injects contrast material into the knee joint prior to contrast knee arthrography or contrast–enhanced CT or MRI knee arthrography to enhance the internal structures such as cartilage,… | 780 | $190 | $147K |
| 73580 | In this procedure, the provider performs imaging supervision and interpretation of a knee joint study. The provider injects contrast material into the knee joint and takes a series of X–rays as it… | 1,220 | $110 | $129.6K |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 21,250 | $10 | $106.3K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 2,280 | $40 | $93.4K |
| J7332 | Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg | 8,160 | $10 | $65.3K |
Showing 1–10 of 18
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 18 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | 60 | $10 | $300 |
| 20610 | In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa and then uses the syringe attachment to the needle to remove fluid or he may inject a… | 300 | $0 | $0 |
| 77002 | The provider uses fluoroscopic guidance to place a needle for biopsy, aspiration, injection, or localization of a device to detect any lesions in any area of the body, except for the spine, or to… | 300 | $0 | $0 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 500 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | 2 | 10 | 2,130 | $100 | $208.2K |
| 20610 | In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa and then uses the syringe attachment to the needle to remove fluid or he may inject a… | 93 | 320 | 120 | $40 | $14.7K |
| 77002 | The provider uses fluoroscopic guidance to place a needle for biopsy, aspiration, injection, or localization of a device to detect any lesions in any area of the body, except for the spine, or to… | 4 | 20 | 60 | $10 | $1.6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 8 | 50 | 60 | $1 | $220 |
Other providers in the same ZIP code as Rahul Khapekar, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| John Hamilton | IL | Anatomic Pathology & Clinical Pathology Physician | $6.4K | $11.7M |
| Medlab Technologies LLC | IL | Clinical Medical Laboratory | $7.3M | $87.6K |
| Michael Pins | IL | Specialist | $67.2K | $5.6M |
| Advocate Health And Hospitals Corporation | IL | General Acute Care Hospital | $0 | $3.9M |
| William Menegas | IL | General Practice Dentistry | $0 | $3.4M |
| Cranial Technologies, Inc. | IL | Prosthetic/Orthotic Supplier | $0 | $3.1M |
| Rajendra Gogia | IL | Pain Medicine (Physical Medicine & Rehabilitation) Physician | $893.5K | $1.6M |
| Oliver Kim | IL | Anatomic Pathology & Clinical Pathology Physician | $98.6K | $2M |
| Andrea Blumstein | IL | Anatomic Pathology & Clinical Pathology Physician | $66.1K | $1.9M |
| City Of Park Ridge | IL | Land Ambulance | $463.9K | $1.1M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.